Results 31 to 40 of about 128,101 (191)
Pharmacological Modulation of BET Family in Sepsis
Frontiers in Pharmacology, 2021 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis 3.0) recommended defining sepsis as a life-threatening organ dysfunction caused by the host's uncontrolled response to infection.
Nian Wang +4 more
doaj +1 more source
BET Bromodomain Proteins as Cancer Therapeutic Targets [PDF]
Cold Spring Harbor Symposia on Quantitative Biology, 2016 Epigenetic regulators are emerging therapeutic targets in a wide variety of human cancers. BET bromodomain proteins have been identified as key regulators of oncogenic transcription factors including MYC; therefore, their inhibition might provide a way to block these "undruggable" targets.
Shaokun, Shu, Kornelia, Polyak
openaire +2 more sources
, 2019 9th Bet Debora Conference "Jewish Women: Being Present, Bringing Change" covered following topics: contemporary women’s perspectives on Jewish tradition; advocacy for other minority groups: activism against antisemitism, antiziganism, racism, and ...
core +7 more sources
Nature Communications, 2023 Bromodomain and extraterminal proteins (BET) are reported as targets for anticancer therapy. Here, the authors report the final results of a phase I clinical trial of the BET inhibitor trotabresib in patients with solid tumours and diffuse large B-cell ...
Victor Moreno +20 more
doaj +1 more source
BET-ting on bromodomains [PDF]
Science-Business eXchange, 2010 A team led by the Dana-Farber Cancer Institute and the Structural Genomics Consortium has identified a selective inhibitor of bromodomains—protein domains that bind and recognize histone acetylation—and has shown its activity in a preclinical model of a rare cancer.
openaire +1 more source
Targeting BET Bromodomains in Cancer
Annual Review of Cancer Biology, 2022 Cancer is frequently dependent on aberrant gene expression programs that might be vulnerable to targeting with novel therapeutics. Bromodomain and extraterminal domain (BET) proteins are powerful transcriptional coregulators often found as part of oncogenic transcriptional programs. The bromodomain functionality of BET proteins is highly druggable, and
openaire +1 more source
Potent and selective bivalent inhibitors of BET bromodomains [PDF]
Nature Chemical Biology, 2016 Proteins of the bromodomain and extraterminal (BET) family, in particular bromodomain-containing protein 4 (BRD4), are of great interest as biological targets. BET proteins contain two separate bromodomains, and existing inhibitors bind to them monovalently.
Michael J Waring +29 more
openaire +3 more sources
The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound
Cell Reports, 2014 N-methyl-2-pyrrolidone (NMP) is a common solvent and drug vehicle. We discovered unexpected antineoplastic and immunomodulatory activity of NMP in a cMYC-driven myeloma model.
Jake Shortt +20 more
doaj +1 more source
Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
Pharmaceuticals, 2022 BET proteins, which recognize and bind to acetylated histones, play a key role in transcriptional regulation. The development of chemical BET inhibitors in 2010 greatly facilitated the study of these proteins.
Dayu Wu, Qiong Duan
doaj +1 more source
Haematologica, 2018 Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors such as OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in hematologic tumors.
Afua A. Mensah +16 more
doaj +1 more source